Eight Capital Initiates Coverage On Field Trip Health With $10.20 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The third company on this list is Field Trip Health (CSE: FTRP) with a C$10.20 12-month price target and buy rating.

Field Trip Health currently has 3 analysts covering the stock with an average 12-month price target of C$16.24. or 182% upside. All 3 analysts have buy ratings. The street high sits at C$20.71 while the lowest comes in at C$10.

Eight Capital says that Field Trip operates in 2 sub-categories of the psychedelic space with one segment focused on providing psychedelic-assisted therapies, while the second segment is a drug development pipeline. The company currently has 7 sites but is expected to expand to 20 that are either in operation or under construction by the end of this year, while having a target of 75 locations by 2024.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Eight Capital calls 2022 a key inflection point for the company as, “there is more demand for healthcare services related to mental health, as 40% of adults reported mental health challenges like depression and anxiety this past year.” Additionally, with major pipeline catalysts coming out of the psychedelic sector in 2022, Field Trip will ultimately benefit from more psychedelic-treatment options coming available.

They also believe that the company’s clinics are differentiated from peers who are doing similar work, since they are focusing on the patient’s mindset and environmental setting to help improve outcomes. They say, “We believe current clinics networks are mostly focused on only administering ketamine treatments, and as a result, clinics do not have the resources, to adequately prepare the patient’s mindset prior to and during infusions.” While Field Trip’s clinics are purposed built with in-house therapists help to set the mindset and setting.

Eight Capital believes that Field Trip is developing the next-generation derivatives of psychedelics. The companies keystone drug is FT-104, which was “developed as an improvement upon the shortcomings of existing psychedelic drugs,” with this drug “trip” time be shorter than the 3-8 hour long timeframe for Ketamine. The company plans to have this drug in a phase 1 trial in the first quarter of 2022 and Eight Capital estimates that it comes to market starting in 2028.

Below you can see the catalysts Eight Capital is looking out for.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Questcorp Begins 600 Metre Phase 2B Drill Program at La Union

Selkirk Copper Wraps 54,579 Metre Phase 2 Program at Minto, Hits 5.97% Copper Equivalent

Related News

Dollarama: Canaccord Lifts Target To $72

Dollarama Inc (TSX: DOL) recently reported its fiscal first-quarter financial results for 2023, ending May...

Saturday, June 25, 2022, 05:06:00 PM

Microsoft: Fiscal Q4 Earnings Consensus Estimates

Microsoft (NASDAQ: MSFT) will be reporting their fiscal fourth quarter financials on July 27 after...

Monday, July 26, 2021, 02:36:00 PM

Curaleaf Sees Consensus Estimates Stay Flat After Q1 Results

Curaleaf Holdings (CSE: CURA) reported its first-quarter results on May 10th, beating the consensus estimates...

Saturday, May 15, 2021, 04:24:00 PM

Green Thumb: Canaccord Lowers Price Target After Earnings Missed Estimates

On November 10th, Green Thumb Industries (CSE: GTII) reported its third quarter financial results. The...

Tuesday, November 16, 2021, 03:27:00 PM

Cineplex: BMO Reiterates Targets Despite Earnings Missing Consensus

Cineplex Inc. (TSX: CGX) reported its second quarter financial results last week. The company announced...

Monday, August 15, 2022, 12:24:00 PM